Q2 2014 Earnings Call
August 08, 2014 8:30 am ET
Neill Bellamy -
Nancy M. Taylor - Chief Executive Officer, President and Director
Kevin A. O'Leary - Chief Financial Officer, Vice President and...
TG Therapeutics, Inc. (NASDAQ:TGTX)
Q2 2014 Earnings Conference Call
July 22, 2014 08:30 AM ET
Jenna Bosco - Director, IR
Sean Power - CFO
Mike Weiss - Interim CEO
Joe Pantginis - ROTH Capital Partners
In a report published Wednesday, MLV & Co. analyst Graig C. Suvannavejh reiterated a Buy rating on TG Therapeutics (NASDAQ: TGTX), and raised the price target from $10.00 to $16.00.
In the report, MLV & Co noted, “We now raise our PT on TGTX...
Vertex Pharmaceuticals (NASDAQ: VRTX) shares moved up 41.68% to $94.37. The volume of Vertex Pharmaceuticals shares traded was 2978% higher than normal. Vertex Pharma reported that its two phase 3 study of Lumacaftor in combination with ivacaftor...
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/TG+Therapeutics+%28TGTX%29+Enters+License+Agreement+for+IRAK4+with+Ligand+%28LGND%29%3B+Will+Get+Stock+%2B+Milestones/9607813.html for the full story.
TG Therapeutics, Inc.
(Nasdaq: TGTX), an innovative, clinical-stage biopharmaceutical company today
announced clinical results from its ongoing Phase I single agent study of
TG-1101 (ublituximab), the Company's novel glycoengineered...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.